← Back to Search

Glucagon-like peptide-1 (GLP-1) receptor agonist

Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (RT1D Trial)

Phase 2

Recruiting

Led By Petter Bjornstad, MD

Research Sponsored by University of Washington

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Stable doses of lipid-lowering medications required for at least 4 weeks prior to randomization, and requested for the duration of the trial

Adults (≥18 years) with type 1 diabetes

Must not have

Personal history of pancreatitis

Other causes of diabetes mellitus, including type 2 diabetes and maturity-onset diabetes of the young (MODY)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 26 weeks

Awards & highlights

Summary

"This trial aims to see how semaglutide affects kidney function and oxygen levels in people with type 1 diabetes. It will also look at how semaglutide impacts blood sugar levels and safety

Who is the study for?

This trial is for adults over 18 with type 1 diabetes who have had the condition for at least five years and are showing signs of kidney disease. They must have stable blood pressure and cholesterol medication use, and women able to have children need to use birth control.

What is being tested?

The study tests if Semaglutide can improve kidney oxygenation and function in people with type 1 diabetes. It also looks at how it affects blood sugar levels and its overall safety compared to a placebo (a treatment with no active drug).

What are the potential side effects?

Possible side effects of Semaglutide may include nausea, vomiting, diarrhea, abdominal pain, low blood sugar events, potential allergic reactions, or injection site reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been on stable doses of my cholesterol medication for at least 4 weeks.

Select...

I am an adult with type 1 diabetes.

Select...

I have had diabetes for 5 years or more.

Select...

My kidney function is normal or only mildly reduced.

Select...

My blood pressure medication dose has been stable for at least 4 weeks.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had pancreatitis before.

Select...

I have a type of diabetes that is not caused by another condition.

Select...

My kidney disease is not caused by diabetes.

Select...

My blood pressure is controlled and not above 160/100 mm Hg.

Select...

My HbA1c is above 9%, or I've had severe diabetes complications or illness requiring hospitalization recently.

Select...

I am not using unapproved diabetes treatments like metformin or SGT-2 inhibitors.

Select...

I've had frequent low blood sugar in the last two weeks.

Select...

I or my family have a history of specific thyroid cancer or I have a thyroid nodule.

Select...

I've had more than 2 severe low blood sugar incidents needing help in the last 6 months.

Select...

I do not have liver disease (except NAFLD) or severe GI issues, and my liver enzymes are normal.

Select...

I am allergic to semaglutide or its ingredients.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 26 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 26 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in kidney cortical relaxation rates (R2*)

Secondary study objectives

Change in estimated glomerular filtration rate

Change in glucose coefficient of variation

Change in glucose time in range

+2 more

Side effects data

From 2020 Phase 4 trial • 104 Patients • NCT04189848

21%

Nausea

12%

Decreased Appetite

100%

80%

60%

40%

20%

Study treatment Arm

Overall Study

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: SemaglutideExperimental Treatment1 Intervention

Semaglutide group from 0.25mg to 1.0mg

Group II: PlaceboPlacebo Group1 Intervention

Placebo group

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Semaglutide

2021

Completed Phase 4

~5160

0 / 16Eligibility criteria met

Find a Location

Who is running the clinical trial?

Juvenile Diabetes Research FoundationOTHER

234 Previous Clinical Trials

142,008 Total Patients Enrolled

Providence HealthcareOTHER

15 Previous Clinical Trials

2,841 Total Patients Enrolled

University of TorontoOTHER

705 Previous Clinical Trials

1,021,491 Total Patients Enrolled

~40 spots leftby Jun 2026

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.